News & Views
Telix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied…
Read more
News,
Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing…
Read more
Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA…
Read more
Telix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15…
Read more
Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68…
Read more
Telix is pleased to announce that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference…
Read more
News,
In collaboration with Cardinal Health, Telix is pleased to announce the launch of a gallium awareness campaign with the release of an in-depth white-paper entitled: “Moving beyond the…
Read more
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL…
Read more
Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product,…
Read more
Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German…
Read more